XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone510-204-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$52.69 million
Profitability
Miscellaneous
Employees12
OptionableNot Optionable
XOMA (NASDAQ:XOMA) Frequently Asked Questions
What is XOMA's stock symbol?
XOMA trades on the NASDAQ under the ticker symbol "XOMA."
How were XOMA's earnings last quarter?
XOMA Corp (NASDAQ:XOMA) posted its quarterly earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.40. The biotechnology company earned $0.90 million during the quarter, compared to analysts' expectations of $0.83 million. XOMA had a negative return on equity of 267.64% and a negative net margin of 129.85%. View XOMA's Earnings History.
When is XOMA's next earnings date?
What price target have analysts set for XOMA?
3 analysts have issued 1-year price targets for XOMA's shares. Their predictions range from $16.26 to $36.00. On average, they anticipate XOMA's share price to reach $28.42 in the next twelve months. This suggests a possible upside of 108.2% from the stock's current price. View Analyst Price Targets for XOMA.
What is the consensus analysts' recommendation for XOMA?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.
What are Wall Street analysts saying about XOMA stock?
Here are some recent quotes from research analysts about XOMA stock:
- 1. HC Wainwright analysts commented, "Valuation disconnect continues even when considering a limited set of current assets. Regarding our valuation of XOMA we believe that the current share price is currently disconnected from the underlying value of even just its opportunity from Novartis (NVS; not rated) partnered assets, led by canakinumab (Ilaris)." (9/21/2018)
- 2. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (8/11/2018)
Has XOMA been receiving favorable news coverage?
Media coverage about XOMA stock has been trending very positive on Monday, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XOMA earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of XOMA's key competitors?
Some companies that are related to XOMA include Odonate Therapeutics (ODT), Akorn (AKRX), Forty Seven (FTSV), Arcus Biosciences (RCUS), Evolus (EOLS), Corbus Pharmaceuticals (CRBP), Clementia Pharmaceuticals (CMTA), Beyondspring (BYSI), Progenics Pharmaceuticals (PGNX), MediciNova (MNOV), ArQule (ARQL), American Brivision (Holding) (ABVC), Synthorx (THOR), Five Prime Therapeutics (FPRX) and Kezar Life Sciences (KZR).
Who are XOMA's key executives?
XOMA's management team includes the folowing people:
- Mr. James R. Neal, CEO & Director (Age 62)
- Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)
- Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)
- Dr. Kirk W. Johnson, VP of Devel. (Age 58)
- Dr. Deepshikha Datta, Chief Bus. Officer
How do I buy shares of XOMA?
Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XOMA's stock price today?
One share of XOMA stock can currently be purchased for approximately $13.65.
How big of a company is XOMA?
XOMA has a market capitalization of $114.49 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.
What is XOMA's official website?
How can I contact XOMA?
XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]
MarketBeat Community Rating for XOMA (NASDAQ XOMA)
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
